JY
RLMD icon

Jeff Yass’s Relmada Therapeutics RLMD Stock Holding History

Jeff Yass’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$208K Sell
30,108
-981,464
-97% -$6.86M ﹤0.01% 11861
2026
Q1 		$7.04M Buy
1,011,572
+625,630
+162% +$2.96M ﹤0.01% 3650
2025
Q4 		$1.86M Buy
385,942
+247,518
+179% +$829K ﹤0.01% 5804
2025
Q3 		$278K Buy
138,424
+72,621
+110% +$69.7K ﹤0.01% 10294
2025
Q2 		$39.5K Buy
+65,803
New +$33.8K ﹤0.01% 12175
2024
Q4 		– Sell
-41,730
Closed -$102K – 13051
2024
Q3 		$135K Sell
41,730
-26,406
-39% -$85.5K ﹤0.01% 10833
2024
Q2 		$204K Buy
68,136
+41,777
+158% +$151K ﹤0.01% 10313
2024
Q1 		$123K Sell
26,359
-16,866
-39% -$81.3K ﹤0.01% 11081
2023
Q4 		$179K Buy
43,225
+13,354
+45% +$39.5K ﹤0.01% 10795
2023
Q3 		$89.6K Sell
29,871
-31,431
-51% -$93.4K ﹤0.01% 11009
2023
Q2 		$151K Sell
61,302
-16,812
-22% -$46.5K ﹤0.01% 10569
2023
Q1 		$177K Sell
78,114
-78,281
-50% -$270K ﹤0.01% 10747
2022
Q4 		$546K Buy
156,395
+117,377
+301% +$1.03M ﹤0.01% 7619
2022
Q3 		$1.44M Buy
+39,018
New +$1.08M ﹤0.01% 5696
2022
Q1 		– Sell
-23,255
Closed -$481K – 13829
2021
Q4 		$524K Sell
23,255
-11,575
-33% -$257K ﹤0.01% 9069
2021
Q3 		$913K Sell
34,830
-33,231
-49% -$889K ﹤0.01% 7812
2021
Q2 		$2.18M Buy
68,061
+6,683
+11% +$232K ﹤0.01% 5715
2021
Q1 		$2.16M Buy
61,378
+49,622
+422% +$1.74M ﹤0.01% 5736
2020
Q4 		$377K Buy
+11,756
New +$404K ﹤0.01% 8844
2020
Q2 		– Sell
-83,566
Closed -$3.53M – 10790
2020
Q1 		$2.85M Buy
83,566
+65,967
+375% +$2.66M ﹤0.01% 3378
2019
Q4 		$686K Buy
+17,599
New +$535K ﹤0.01% 6299

Other funds holding RLMD

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jeff Yass's RLMD Position: Q2 2026 in Review

Jeff Yass reduced its Relmada Therapeutics (RLMD) stake by 97% in Q2 2026, selling an estimated $6.86M and leaving 30,108 shares worth $208K. The position accounts for ﹤0.01% of the portfolio, ranked #11861.

Jeff Yass first reported a position in RLMD in Q4 2019 and has held it in 21 quarters since. The position peaked at $7.04M in Q1 2026. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • Jeff Yass held 30,108 shares of Relmada Therapeutics worth $208K as of Q2 2026.
  • Jeff Yass sold 981,464 Relmada Therapeutics shares in Q2 2026, an estimated $6.86M.
  • Relmada Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #11861 holding.
  • Jeff Yass first reported a position in Relmada Therapeutics in Q4 2019 and has held it in 21 quarters since.
  • Jeff Yass's Relmada Therapeutics position peaked at $7.04M in Q1 2026.
  • 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.